Join
Live feed
·
ANALYSTRatingvia Quantisnow
enGene Therapeutics Inc. logo

enGene Therapeutics downgraded by Raymond James with a new price target

ByQuantisnow·Wall Street's wire, on your screen.
ENGN· enGene Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENGN (enGene Therapeutics Inc.) and more on Quantisnow.

enGene Therapeutics downgraded by Raymond James with a new price target | Quantisnow